Document Detail


Nebulized albuterol for acute hyperkalemia in patients on hemodialysis.
MedLine Citation:
PMID:  2919849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVE: To determine the efficacy and safety of nebulized albuterol in the acute treatment of hyperkalemia in patients on chronic hemodialysis. DESIGN: Prospective, double-blind, and placebo-controlled study. SETTING: Outpatient hemodialysis clinic at a university medical center. PATIENTS: Ten patients on maintenance hemodialysis who had chronic hyperkalemia. INTERVENTIONS: Patients received nebulized albuterol therapy (10 mg or 20 mg) or placebo (saline) on three separate occasions, serial measurements of plasma potassium levels, blood pressure, and pulse were then taken for a 2-hour period. MEASUREMENTS AND MAIN RESULT: Patients had a significant decrease in plasma potassium concentrations that was evident by 30 minutes and sustained for at least 2 hours after albuterol treatment. After the administration of 10- and 20-mg doses of albuterol, the maximal decrease in the plasma potassium levels was 0.62 +/- 0.09 and 0.98 +/- 0.14 mmol/L (SE), respectively. Nebulized saline administration did not produce a significant change in the plasma potassium concentrations. Patients did not develop symptoms or significant changes in blood pressure or heart rate with albuterol treatment. CONCLUSIONS: In the doses used, nebulized albuterol therapy resulted in a prompt and significant decrease in the plasma potassium concentrations in patients on hemodialysis, and caused no adverse cardiovascular effects. This treatment should be considered as an important adjunct for acute treatment of serious hyperkalemia in this population of patients.
Authors:
M Allon; R Dunlay; C Copkney
Related Documents :
12753269 - Evolution of serum phosphate in long intermittent hemodialysis.
1565179 - Beta-2-microglobulin-derived amyloidosis: onset, distribution and clinical features in ...
19758299 - Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis.
8821199 - Serum soluble interleukin 2 receptor in hemodialysis patients treated with recombinant ...
17689389 - Cerebral microbleeds and intracerebral hemorrhages in patients on maintenance hemodialy...
11169019 - Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Annals of internal medicine     Volume:  110     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  1989 Mar 
Date Detail:
Created Date:  1989-03-29     Completed Date:  1989-03-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  426-9     Citation Subset:  AIM; IM    
Affiliation:
University of Oklahoma School of Medicine, Oklahoma City.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aerosols
Aged
Albuterol / administration & dosage,  adverse effects,  therapeutic use*
Blood Pressure / drug effects
Double-Blind Method
Drug Evaluation
Drug Resistance
Heart Rate / drug effects
Humans
Hyperkalemia / drug therapy*
Middle Aged
Prospective Studies
Renal Dialysis*
Chemical
Reg. No./Substance:
0/Aerosols; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in oxygenation and pulse rate during endoscopy.
Next Document:  Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?